Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03427814 · ClinicalTrials.gov registry record · Phase 2
Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer
A Phase 2 study of Advanced or Inoperable Gastric Cancer, sponsored by BeiGene.
- Completed
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
- 20
- Study locations
NCT03427814 is a Phase 2 study of Advanced or Inoperable Gastric Cancer that has completed, run by BeiGene. The registered enrollment target is 136 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT03427814, a Phase 2 study of Advanced or Inoperable Gastric Cancer, has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study enrolled participants with previously-treated advanced or inoperable gastric cancer who have responded to first line platinum therapy into two treatment arms. In Arm A participants received BGB-290; in Arm B participants received placebo. The purpose of this study is to show that BGB-290 (pamiparib) (versus placebo) will improve progression-free survival (PFS) in participants with advanced or inoperable gastric cancer.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pamiparib
Study Locations (20)
Guangdong
- Sun Yat Sen University Cancer Center - Guangzhou
- Nanfang Hospital of Southern Medical University - Guangzhou
- Cancer Hospital of Shantou University Medical College - Shantou
Florida
- Miami Cancer Institute - Miami
- Scri Florida Cancer Specialist East - West Palm Beach
Victoria
- Monash Health - Clayton
- Ballarat Oncology and Haematology Services - Wendouree
Other
- Az Sint Jan Brugge - Bruges
- University Hospitals Leuven - Leuven
Indiana
- Goshen Center For Cancer Care - Goshen
Kansas
- Cancer Center of Kansas - Wichita
Kentucky
- Norton Cancer Institute - Louisville
North Carolina
- Novant Health Hematology Charlotte - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2018-07-03 |
| Est. Completion | 2023-01-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03427814
The ClinicalTrials.gov registry entry for NCT03427814 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced or Inoperable Gastric Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03427814 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Guangdong, Florida, Victoria.
Frequently Asked Questions
What is clinical trial NCT03427814 about?
NCT03427814 is a clinical study titled "Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer". This study enrolled participants with previously-treated advanced or inoperable gastric cancer who have responded to first line platinum therapy into two treatment arms. In Arm A participants received BGB-290; in Arm B participants received placebo. The purpose of this study is to show that BGB-290 ...
What is the current status of trial NCT03427814?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2018-07-03. Estimated completion is 2023-01-03.
What conditions does trial NCT03427814 study?
This clinical trial studies the following conditions: Advanced or Inoperable Gastric Cancer.
What interventions are being tested in trial NCT03427814?
The interventions under investigation include: Placebo (DRUG), Pamiparib (DRUG).
Who is sponsoring clinical trial NCT03427814?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03427814 being conducted?
This trial has 20 study locations across Florida, Indiana, Kansas, Kentucky, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.